Metastatic melanoma treatment: Combining old and new therapies

Critical Reviews in Oncology/Hematology

Volumn 98, Issue , 2016, Pages 242-253

  Davey, Ryan J ^a   Westhuizen, Andre van der ^b   Bowden, Nikola A ^a  

^a UNIVERSITY OF NEWCASTLE   (Australia)

^b CALVARY MATER NEWCASTLE HOSPITAL   (Australia)

Author keywords

Combination therapy; Immunotherapy; Melanoma; Targeted therapy; Treatment

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; B RAF KINASE INHIBITOR; DACARBAZINE; FOTEMUSTINE; INTERLEUKIN 2; IPILIMUMAB; KIT INHIBITOR; MELANOMA VACCINE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE KINASE INHIBITOR; NIVOLUMAB; NRAS INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROGRAMMED DEATH 1 RECEPTOR ANTAGONIST; RAC1 INHIBITOR; RECEPTOR BLOCKING AGENT; TEMOZOLAMIDE; UNCLASSIFIED DRUG; B RAF KINASE; GUANOSINE TRIPHOSPHATASE; MEMBRANE PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE KINASE; NRAS PROTEIN, HUMAN; PROGRAMMED DEATH 1 RECEPTOR;

ANGIOGENESIS; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CANCER RESISTANCE; DISEASE MARKER; DRUG DEVELOPMENT; DRUG EFFICACY; HUMAN; METASTATIC MELANOMA; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; NONHUMAN; PATIENT SELECTION; REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; ADOPTIVE IMMUNOTHERAPY; ANTAGONISTS AND INHIBITORS; GENETICS; IMMUNOTHERAPY; MELANOMA; MUTATION; SECONDARY;

GTP PHOSPHOHYDROLASES; HUMANS; IMMUNOTHERAPY; IMMUNOTHERAPY, ADOPTIVE; INTERLEUKIN-2; MELANOMA; MEMBRANE PROTEINS; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; MOLECULAR TARGETED THERAPY; MUTATION; PROGRAMMED CELL DEATH 1 RECEPTOR; PROTO-ONCOGENE PROTEINS B-RAF; PTEN PHOSPHOHYDROLASE;

EID: 84957441530     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2015.11.011     Document Type: Review

References (177)

1. Abbotts R., et al. Targeting human apurinic/apyrimidinic endonuclease 1 (APE1) in phosphatase and tensin homolog (PTEN) deficient melanoma cells for personalized therapy. Oncotarget 2014, 5(10):3273-3286.
2. Aguissa-Toure A.H., Li G. Genetic alterations of PTEN in human melanoma. Cell. Mol. Life Sci. 2012, 69(9):1475-1491.
3. Albino A.P., et al. Transforming ras genes from human melanoma: a manifestation of tumour heterogeneity?. Nature 1984, 308(5954):69-72.
4. Alexandrescu D.T., et al. Immunotherapy for melanoma: current status and perspectives. J. Immunother. 2010, 33(6):570-590.
5. Ascierto P.A., et al. MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, opem label pahse 2 study. Lancet Oncol. 2013, 14(3):249-256.
6. Atkins M.B., et al. High-dose recombinant interleukin2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J. Clin. Oncol. 1999, 17(7):2105-2116.
7. Avril M.F., et al. Fotemustine compared with dacarbazine in patients with diesseminated malignant melanoma: a phase III study. J. Clin. Oncol. 2004, 22(6):1118-1125.
8. Bedognetti D., et al. CXCR3/CCR5 pathways in metastatic melanoma patients treated with adoptive therapy and interleukin-2. Br. J. Cancer 2013, 109(9):2412-2423.
9. Berger M.F., et al. Melanoma genome sequencing reveals frequent PREX2 mutations. Nature 2012, 485:502-506.
10. Besser M.J., et al. Adoptive transfer of tumor-infiltrating lymphocytes in patients with metastatic melanoma: intent-to-treat analysis and efficacy after failure to prior immunotherapies. Clin. Cancer Res. 2013, 19(17):4792-4800.
11. Blank C.U., Enk A. Therapeutic use of anti-CTLA-4 antibodies. Int. Immunol. 2014.
12. Blank C.U., et al. Combination of targeted therapy and immunotherapy in melanoma. Cancer Immunol. Immunother. 2011, 60(10):1359-1371.
13. Bogunovic D., et al. TLR4 engagement during TLR3-induced proinflammatory signaling in dendritic cells promotes IL-10-mediated suppression of antitumor immunity. Cancer Res. 2011, 71(16):5467-5476.
14. Boni A., et al. Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Res. 2010, 70(13):5213-5219.
15. Boone B., et al. EGFR in melanoma: clinical significance and potential therapeutic target. J. Cutan. Pathol. 2011, 38(6):492-502.
16. Bos J.L. ras oncogenes in human cancer: a review. Cancer Res. 1989, 49(17):4682-4689.
17. Bucheit A.D., Davies M.A. Emerging insights into resistance to BRAF inhibitors in melanoma. Biochem. Pharmacol. 2014, 87(3):381-389.
18. Bucheit A.D., et al. Clinical characteristics and outcomes with specific BRAF and NRAS mutations in patients with metastatic melanoma. Cancer 2013, 119(21):3821-3829.
19. Carretero R., et al. Regression of melanoma metastases after immunotherapy is associated with activation of antigen presentation and interferon-mediated rejection genes. Int. J. Cancer 2012, 131(2):387-395.
20. Comin-Anduix B., et al. Detailed analysis of immunologic effects of the cytotoxic T lymphocyte-associated antigen 4-blocking monoclonal antibody tremelimumab in peripheral blood of patients with melanoma. J. Transl. Med. 2008, 6:22.
21. Conrad W.H., et al. Regulating the response to targeted MEK inhibition in melanoma: enhancing apoptosis in NRAS- and BRAF-mutant melanoma cells with Wnt/beta-catenin activation. Cell Cycle 2012, 11(20):3724-3730.
22. Curran M.A., et al. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc. Natl. Acad. Sci. U. S. A. 2010, 107(9):4275-4280.
23. Davies H., et al. Mutations of the BRAF gene in human cancer. Nature 2002, 417(6892):949-954.
24. Devitt B., et al. Clinical outcome and pathological features associated with NRAS mutation in cutaneous melanoma. Pigm. Cell Melanoma Res. 2011, 24(4):666-672.
25. de Silva C.M., Reid R. Gastrointestinal stromal tumors (GIST): C-kit mutations, CD117 expression, differential diagnosis and targeted cancer therapy with imatinib. Pathol. Oncol. Res. 2003, 9(1):13-19.
26. Di Giacomo A.M., et al. Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial. Lancet Oncol. 2012, 13(9):879-886.
27. Di Giacomo A.M., et al. Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian network for tumor biotherapy (NIBIT)-M1 phase II study. Ann. Oncol. 2015, 26(4):798-803.
28. Dong J., et al. In vitro expansion of T cells stimulated by combination of IL-2: IL-7 and IL-15. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2010, 18(6):1590-1594.
29. Dong L., et al. Oncogenic suppression of PHLPP1 in human melanoma. Oncogene 2013, 33(39):4756-4766.
30. Dong Y., et al. PTEN functions as a melanoma tumor suppressor by promoting host immune response. Oncogene 2013, 33(38):4632-4642.
31. Downward J. Targeting RAS signalling pathways in cancer therapy. Nat. Rev. Cancer 2003, 3(1):11-22.
32. Drake C.G., Lipson E.J., Brahmer J.R. Breathing new life into immunotherapy: melanoma, ling and kidney cancer. Nat. Rev. Clin. Oncol. 2014, 11:24-37.
33. Dudley M.E., et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002, 298(5594):850-854.
34. Dudley M.E., et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J. Clin. Oncol. 2008, 26(32):5233-5239.
35. Eccles M.R. Melanoma genetics/genomics. Front. Oncol. 2013, 3:309.
36. Eggermont A.M., Kirkwood J.M. Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years?. Eur. J. Cancer 2004, 40:1825-1836.
37. Elias E.G., et al. GM-CSF and IL-2 combination as adjuvant therapy in cutaneous melanoma: early results of a phase II clinical trial. Oncology (Williston Park) 2005, 19(4 Suppl. 2):15-18.
38. Eskandarpour M., et al. Oncogenic NRAS has multiple effects on the malignant phenotype of human melanoma cells cultured in vitro. Int. J. Cancer 2009, 124(1):16-26.
39. Frederick D.T., et al. BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin. Cancer Res. 2013, 19(5):1225-1231.
40. Freeman G.J., et al. Cloning of B7-2: a CTLA-4 counter-receptor that costimulates human T cell proliferation. Science 1993, 262(5135):909-911.
41. Fruehauf J., et al. Multicenter, phase II study of axitinib, a selective second-generation inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, in patients with metastatic melanoma. Clin. Cancer Res. 2011, 17(23):7462-7469.
42. Gajewski T.F., et al. Phase II. study of the farnesyltransferase inhibitor R115777 in advanced melanoma (CALGB 500104). J. Transl. Med. 2012, 10:246.
43. Gajewski T.F. Identifying and overcoming immune resistance mechanisms in the melanoma tumor microenvironment. Clin. Cancer Res. 2006, 12(7 pt 2):2326-2330.
44. Galon J., et al. The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures. Immunity 2013, 39(1):11-26.
45. Garbe C., et al. Systematic review of medical treatment in melanoma: current status and future prospects. Oncologist 2011, 16(1):5-24.
46. Guo J., et al. Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. J. Clin. Oncol. 2011, 29(21):2904-2909.
47. Guo C., et al. Therapeutic cancer vaccines: past, present, and future. Adv. Cancer Res. 2013, 119:421-475.
48. Hamid O., et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N. Engl. J. Med. 2013, 369(2):134-144.
49. Handolias D., et al. Mutations in KIT occur at low frequency in melanomas arising from anatomical sites associated with chronic and intermittent sun exposure. Pigm. Cell Melanoma Res. 2010, 23(2):210-215.
50. Hauschild A., et al. Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J. Clin. Oncol. 2009, 27(17):2823-2830.
51. Hauschild A., et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multi-centre, open label, phase 3 randomised controlled trial. Lancet 2012, 380:358-365.
52. Hayward N. New developments in melanoma genetics. Curr. Oncol. Rep. 2000, 2(4):300-306.
53. Heakal Y., Kester M., Savage S. Vemurafenib (PLX4032): an orally available inhibitor of mutated BRAF for the treatment of metastatic melanoma. Ann. Pharmacother. 2011, 45(11):1399-1405.
54. Hersh E.M., et al. A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naive patients with advanced melanoma. Invest. New Drugs 2011, 29(3):489-498.
55. Hervieu A., et al. Dacarbazine-mediated upregulation of NKG2D ligands on tumor cells activates NK and CD8 T cells and restrains melanoma growth. J. Invest. Dermatol. 2013, 133(2):499-508.
56. Hervieu A., Mignot G., Ghiringhelli F. Dacarbazine mediate antimelanoma effects via NK cells. Oncoimmunology 2013, 2(4):e23714.
57. Hill V.K., et al. The genetics of melanoma: recent advances. Annu. Rev. Genom. Hum. Genet. 2013, 14:257-279.
58. Hingorani S.R., et al. Suppression of BRAF(V599E) in human melanoma abrogates transformation. Cancer Res. 2003, 63(17):5198-5202.
59. Hodis E., et al. A landscape of driver mutations in melanoma. Cell 2012, 150(2):251-263.
60. Huncharek M., Caubet J.F., McGarry R. Single-agent DTIC versus combination chemotherapy with or without immunotherapy in metastatic melanoma: a meta-analysis of 3273 patients from 20 randomized trials. Melanoma Res. 2001, 11:75-81.
61. Jakob J.A., et al. NRAS mutation status is an independent prognostic factor in metastatic melanoma. Cancer 2012, 118(16):4014-4023.
62. Jazirehi A.R., Wenn P.B., Damavand M. Therapeutic implications of targeting the PI3kinase/AKT/mTOR signaling module in melanoma therapy. Am. J. Cancer Res. 2012, 2(2):178-191.
63. Jensen B.A., et al. The availability of a functional tumor targeting T-cell repertoire determines the anti-tumor efficiency of combination therapy with anti-CTLA-4 and anti-4-1BB antibodies. PLoS One 2013, 8(6):e66081.
64. Ji R.R., et al. An immune-active tumor microenvironment favors clinical response to ipilimumab. Cancer Immunol. Immunother. 2012, 61(7):1019-1031.
65. Jin G.X., et al. Establishment of mouse melanoma model expressing beta-galactosidase and its application in the research of DNA vaccines against tumor. Shi Yan Sheng Wu Xue Bao 2004, 37(5):339-343.
66. Jin H., et al. Matrine activates PTEN to induce growth inhibition and apoptosis in V600EBRAF harboring melanoma cells. Int. J. Mol. Sci. 2013, 14(8):16040-16057.
67. Johannessen C.M., et al. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 2010, 468(7326):968-972.
68. Johnson D.B., Puzanov I. Treatment of NRAS-mutant melanoma. Curr. Treat. Options Oncol. 2015, 16(15).
69. Johnson L.A., et al. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 2009, 114(3):535-546.
70. Joseph R.W., et al. Correlation of NRAS mutations with clinical response to high-dose IL-2 in patients with advanced melanoma. J. Immunother. 2012, 35(1):66-72.
71. Kaplan M.G. Ipilimumab plus dacarbazine in melanoma. N. Engl. J. Med. 2011, 365(13):1256-1257. (author reply 1257-8).
72. Kawakami Y., et al. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc. Natl. Acad. Sci. U. S. A. 1994, 91(14):6458-6462.
73. Kawakami Y., et al. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc. Natl. Acad. Sci. U. S. A. 1994, 91(9):3515-3519.
74. Kefford R.F., et al. Counseling and DNA testing for individuals perceived to be genetically predisposed to melanoma: a consensus statement of the melanoma genetics consortium. J. Clin. Oncol. 1999, 17(10):3245-3251.
75. Keilholz U., et al. Prognostic factors for survival and factors associated with long-term remission in patients with advanced melanoma receiving cytokine-based treatments: second analysis of a randomised EORTC melanoma group trial comparing interferon-a2a (IFNa) and interleukin 2 (IL-2) with or without cisplatin. Eur. J. Cancer 2002, 38:1501-1511.
76. Khalili J.S., et al. Oncogenic BRAF(V600E) promotes stromal cell-mediated immunosuppression via induction of interleukin-1 in melanoma. Clin. Cancer Res. 2012, 18(19):5329-5340.
77. Kim M.O., et al. Embryonic stem-cell-preconditioned microenvironment induces loss of cancer cell properties in human melanoma cells. Pigm. Cell Melanoma Res. 2011, 24(5):922-931.
78. Kim K.B., et al. Phase II. study of the MEK1/MEK2 inhibitor trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. J. Clin. Oncol. 2013, 31(4):482-489.
79. King A.J., et al. Dabrafenib; preclinical characterization, increased efficacy when combined with trametinib, while BRAF/MEK tool combination reduced skin lesions. PLoS One 2013, 8(7):e67583.
80. Kirkwood J.M., Tarhini A.A. Biomarkers of therapeutic response in melanoma and renal cell carcinoma: potential inroads to improved immunotherapy. J. Clin. Oncol. 2009, 27(16):2583-2585.
81. Klebanoff C.A., et al. Therapeutic cancer vaccines: are we there yet?. Immunol. Rev. 2011, 239(1):27-44.
82. Koefinger P., et al. The cadherin switch in melanoma instigated by HGF is mediated through epithelial-mesenchymal transition regulators. Pigm. Cell Melanoma Res. 2011, 24(2):382-385.
83. Konstantinopoulos P.A., Karamouzis M.V., Papavassiliou A.G. Post-translational modifications and regualtion of the RAS superfamily of GTPases as anticancer targets. Nat. Rev. Drug Discov. 2007, 6:541-555.
84. Krauthammer M., et al. Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. Nat. Genet. 2012, 44(9):1006-1014.
85. Kruit W.H., et al. Selection of immunostimulant AS15 for active immunization with MAGE-A3 protein: results of a randomized phase II study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma. J. Clin. Oncol. 2013, 31(19):2413-2420.
86. Langer C.J. Emerging immunotherapies in the treatment of non-small cell lung cancer (nsclc): the role of immune checkpoint inhibitors. Am. J. Clin. Oncol. 2015, 38(4):422-430.
87. Larkin J., Hodi F.S., Wolchok J.D. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N. Engl. J. Med. 2015, 373(13):1270-1271.
88. Lawrence M.S., et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 2013, 499(7457):214-218.
89. Le H.K., et al. Incubation of antigen-sensitized T lymphocytes activated with bryostatin 1 + ionomycin in IL-7 + IL-15 increases yield of cells capable of inducing regression of melanoma metastases compared to culture in IL-2. Cancer Immunol. Immunother. 2009, 58(10):1565-1576.
90. Lens M. The role of vaccine therapy in the treatment of melanoma. Expert Opin. Biol. Ther. 2008, 8(3):315-323.
91. Li A., Machesky L.M. Melanoblasts on the move: rac1 sets the pace. Small GTPases 2012, 3(2):115-119.
92. Lindsay J.N., Barras M. Facing the challenges of new melanoma-targeted therapies: treatment of severe fevers associated with dabrafenib/trametinib combination therapy. J. Oncol. Pharm. Pract. 2015, 21(4):293-295.
93. Lito P., Rosen N., Solit D.B. Tumor adaptation and resistance to RAF inhibitors. Nat. Med. 2013, 19(11):1401-1409.
94. Liu B.L., et al. ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties. Gene Ther. 2003, 10(4):292-303.
95. Liu C., et al. BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice. Clin. Cancer Res. 2013, 19(2):393-403.
96. Lo R.S., Shi H. Detecting mechanisms of acquired BRAF inhibitor resistance in melanoma. Methods Mol. Biol. 2014, 1102:163-174.
97. Long G.V., et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet 2015, 386(9992):444-451.
98. Lucchetti C., et al. Research highlights. Overcoming BRAF resistance to PLX4032 by AKT inhibition in PTEN-deficient melanoma cells. Pharmacogenomics 2011, 12(10):1381.
99. Luke J.J., Hodi F.S. Vemurafenib and BRAF inhibition: a new class of treatment for metastatic melanoma. Clin. Cancer Res. 2012, 18(1):9-14.
100. Luke J.J., Ott P.A. New developments in the treatment of metastatic melanoma-role of dabrafenib-trametinib combination therapy. Drug Healthc Patient Saf. 2014, 6:77-88.
101. Luke J.J., et al. Clinical activity of ipilimumab for metastatic uveal melanoma: a retrospective review of the Dana-Farber cancer institute, massachusetts general hospital, memorial sloan-kettering cancer center, and university hospital of lausanne experience. Cancer 2013, 119(20):3687-3695.
102. Madhunapantula S.V., Robertson G.P. Therapeutic implications of targeting akt signaling in melanoma. Enzyme Res. 2011, 2011:327923.
103. Maertens O., et al. Elucidating distinct roles for NF1 in melanomagenesis. Cancer Discov. 2013, 3(3):338-349.
104. Mamalis A., Garcha M., Jagdeo J. Targeting the PD-1 pathway: a promising future for the treatment of melanoma. Arch. Dermatol. Res. 2014, 306(6):511-519.
105. Mani A., et al. A phase II trial of trastuzumab in combination with low-dose interleukin-2 (IL-2) in patients (PTS) with metastatic breast cancer (MBC) who have previously failed trastuzumab. Breast Cancer Res. Treat. 2009, 117(1):83-89.
106. Marchand M., et al. Biological and clinical developments in melanoma vaccines. Expert Opin. Biol. Ther. 2001, 1(3):497-510.
107. Massi D., et al. The status of PD-L1 and tumor-infiltrating immune cells predict resistance and poor prognosis in BRAFi-treated melanoma patients harboring mutant BRAFV600. Ann. Oncol. 2015, 26(9):1980-1987.
108. McDermott D., et al. Durable benefit and the potential for long-term survival with immunotherapy in advanced melanoma. Cancer Treat. Rev. 2014, 40(9):1056-1064.
109. Mellman I., Coukos G., Dranoff G. Cancer immunotherapy comes of age. Nature 2011, 480:480-489.
110. Menzies A.M., Long G.V. Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma. Clin. Cancer Res. 2014, 20(8):2035-2043.
111. Middleton M.R., et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J. Clin. Oncol. 2000, 18(1):158-166.
112. Morris E.J., et al. Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors. Cancer Discov. 2013, 3(7):742-750.
113. Mullen J.T., Tanabe K.K. Viral oncolysis. Oncologist 2002, 7(2):106-119.
114. Muul L.M., et al. Identification of specific cytolytic immune responses against autologous tumor in humans bearing malignant melanoma. J. Immunol. 1987, 138(3):989-995.
115. Nazarian R., et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 2010, 468(7326):973-977.
116. Njoroge F.G., et al. Trihalobenzocycloheptapyridine analogues of Sch 66336 as potent inhibitors of farnesyl protein transferase. Bioorg. Med. Chem. 2003, 11(1):139-143.
117. Ong C.C., et al. p21-activated kinase 1: PAK'ed with potential. Oncotarget 2011, 2(6):491-496.
118. Ott P.A., Hodi F.S., Robert C. CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients. Clin. Cancer Res. 2013, 19(19):5300-5309.
119. Paraiso K.H., et al. PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression. Cancer Res. 2011, 71(7):2750-2760.
120. Pardoll D.M. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 2012, 12:252-264.
121. Paschka P., et al. Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a cancer and leukemia group B study. J. Clin. Oncol. 2006, 24(24):3904-3911.
122. Peters S., et al. Dramatic response of vemurafenib-induced cutaneous lesions upon switch to dual BRAF/MEK inhibition in a metastatic melanoma patient. Melanoma Res. 2014, 24(5):496-500.
123. Pilon-Thomas S., et al. Efficacy of adoptive cell transfer of tumor-infiltrating lymphocytes after lymphopenia induction for metastatic melanoma. J. Immunother. 2012, 35(8):615-620.
124. Pleasance E.D., et al. A comprehensive catalogue of somatic mutations from a human cancer genome. Nature 2010, 463(7278):191-196.
125. Postow M.A., et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N. Engl. J. Med. 2015, 372(21):2006-2017.
126. Poulikakos P.I., et al. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature 2011, 480(7377):387-390.
127. Prestwich R.J., et al. The case of oncolytic viruses versus the immune system: waiting on the judgment of Solomon. Hum. Gene Ther. 2009, 20(10):1119-1132.
128. Quast S.A., Berger A., Eberle J. ROS-dependent phosphorylation of Bax by wortmannin sensitizes melanoma cells for TRAIL-induced apoptosis. Cell Death Dis. 2013, 4:e839.
129. Radvanyi L.G., et al. Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients. Clin. Cancer Res. 2012, 18(24):6758-6770.
130. Razzak M. From ASCO-targeted therapies: Anti-PD-1 approaches-important steps forward in metastatic melanoma. Nat. Rev. Clin. Oncol. 2013, 10(7):365.
131. Ribas A., et al. Hepatotoxicity with combination of vemurafenib and ipilimumab. N. Engl. J. Med. 2013, 368(14):1365-1366.
132. Riley J.L. Combination checkpoint blockade-taking melanoma immunotherapy to the next level. N. Engl. J. Med. 2013, 369(2):187-189.
133. Robert C., et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N. Engl. J. Med. 2011, 364(26):2517-2526.
134. Robert C., Soria J.C., Eggermont A.M. Drug of the year: programmed death-1 receptor/programmed death-1 ligand-1 receptor monoclonal antibodies. Eur. J. Cancer 2013, 49(14):2968-2971.
135. Robert C., et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet 2014, 384(9948):1109-1117.
136. Rosenberg S.A., Restifo N.P. Adoptive cell transfer as personalized immunotherapy for human cancer. Science 2015, 348(6230):62-68.
137. Rosenberg S.A., et al. Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2. J. Exp. Med. 1985, 161(5):1169-1188.
138. Rosenberg S.A., et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N. Engl. J. Med. 1988, 319(25):1676-1680.
139. Rosenberg S.A., et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA 1994, 271(12):907-913.
140. Rosenberg S.A., et al. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J. Natl. Cancer. Inst. 1994, 86(15):1159-1166.
141. Rosenberg S.A., et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin. Cancer Res. 2011, 17(13):4550-4557.
142. Russell S.J., Peng K.W., Bell J.C. Oncolytic virotherapy. Nat. Biotechnol. 2012, 30(7):658-670.
143. Schadendorf D., et al. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimimab in unresectable or metastatic melanoma. J. Clin. Oncol. 2015, 33(17):1889-1894.
144. Schwartzentruber D.J., et al. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N. Engl. J. Med. 2011, 364(22):2119-2127.
145. Senzer N.N., et al. Phase II. clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. J. Clin. Oncol. 2009, 27(34):5763-5771.
146. Shi H., et al. Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. Cancer Discov. 2014, 4:80-93.
147. Shull A.Y., et al. Novel somatic mutations to PI3K pathway genes in metastatic melanoma. PLoS One 2012, 7(8):e43369.
148. Sivanandham M., Kim E.M., Wallack M.K. Experimental melanoma vaccines. IDrugs 2002, 5(2):159-170.
149. Smalley K.S., Eisen T.G. Farnesyl transferase inhibitor SCH66336 is cytostatic, pro-apoptotic and enhances chemosensitivity to cisplatin in melanoma cells. Int. J. Cancer 2003, 105(2):165-175.
150. Sondak V.K., et al. Ipilimumab. Nat. Rev. Drug Discov. 2011, 10(6):411-412.
151. Sosman J.A., et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N. Engl. J. Med. 2012, 366(8):707-714.
152. Srivastava N., McDermott D. Update on benefit of immunotherapy and targeted therapy in melanoma: the changing landscape. Cancer Manag. Res. 2014, 6:279-289.
153. Stark M.S., et al. Frequent somatic mutations in MAP3K5 and MAP3K9 in metastatic melanoma identified by exome sequencing. Nat. Genet. 2012, 44(2):165-169.
154. Su F., et al. Resistance to selective BRAF inhibition can be mediated by modest upstream pathway activation. Cancer Res. 2012, 72(4):969-978.
155. Sullivan R.J., Flaherty K.T. Resistance to BRAF-targeted therapy in melanoma. Eur. J. Cancer 2013, 49(6):1297-1304.
156. Terando A.M., Faries M.B., Morton D.L. Vaccine therapy for melanoma: current status and future directions. Vaccine 2007, 2(25 Suppl):B4-16.
157. Thumar J., et al. MEK targeting in N-RAS mutated metastatic melanoma. Mol. Cancer 2014, 13:45.
158. Tomei S., et al. The immune-related role of BRAF in melanoma. Mol. Oncol. 2014, 9(1):93-104.
159. Topalian S.L., et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 2012, 366(26):2443-2454.
160. Topcu-Yilmaz P., et al. Correlation of clinicopathological parameters with HGF, c-Met, EGFR, and IGF-1R expression in uveal melanoma. Melanoma Res. 2010, 20(2):126-132.
161. Traversari C., et al. A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E. J. Exp. Med. 1992, 176(5):1453-1457.
162. Tumeh P.C., et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 2014, 515:568-571.
163. Varker K.A., et al. A randomized phase 2 trial of bevacizumab with or without daily low-dose interferon alfa-2b in metastatic malignant melanoma. Ann. Surg. Oncol. 2007, 14(8):2367-2376.
164. Villanueva J., et al. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell 2010, 18(6):683-695.
165. Wagle N., et al. Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J. Clin. Oncol. 2011, 29(22):3085-3096.
166. Wang E., Bedognetti D., Marincola F.M. Prediction of response to anticancer immunotherapy using gene signatures. J. Clin. Oncol. 2013, 31(19):2369-2371.
167. Weber J., et al. White paper on adoptive cell therapy for cancer with tumor-infiltrating lymphocytes: a report of the CTEP subcommittee on adoptive cell therapy. Clin. Cancer Res. 2011, 17(7):1664-1673.
168. Weber J.S., et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2015, 16(4):375-384.
169. Wei X., et al. Exome sequencing identifies GRIN2A as frequently mutated in melanoma. Nat. Genet. 2011, 43(5):442-446.
170. Weiss G.R., et al. Molecular insights on the peripheral and intratumoral effects of systemic high-dose rIL-2 (aldesleukin) administration for the treatment of metastatic melanoma. Clin. Cancer Res. 2011, 17(23):7440-7450.
171. Werzowa J., et al. Vertical inhibition of the mTORC1/mTORC2/PI3K pathway shows synergistic effects against melanoma in vitro and in vivo. J. Invest. Dermatol. 2011, 131(2):495-503.
172. Whittaker S.R., et al. A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition. Cancer Discov. 2013, 3(3):350-362.
173. Wilmott J.S., et al. Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma. Clin. Cancer Res. 2012, 18(5):1386-1394.
174. Wolchok J.D., et al. Nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med. 2013, 369(2):122-133.
175. Yajima I., et al. RAS/RAF/MEK/ERK and PI3K/PTEN/AKT signaling in malignant melanoma progression and therapy. Dermatol. Res. Pract. 2012, 2012:354191.
176. Yamada K., et al. Phase I. dose-escalation study and biomarker analysis of E7080 in patients with advanced solid tumors. Clin. Cancer Res. 2011, 17(8):2528-2537.
177. Zhao J., et al. Flumatinib, a selective inhibitor of BCR-ABL/PDGFR/KIT, effectively overcomes drug resistance of certain KIT mutants. Cancer Sci. 2013, 105(1):117-125.